A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Aripiprazole lauroxil (Primary) ; Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Alkermes plc
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.
- 15 Nov 2017 Status changed from planning to not yet recruiting.
- 27 Oct 2017 New trial record